Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone

Gain of chromosome 1q (+1q) is commonly identified in multiple myeloma and has been associated with inferior outcomes. However, the prognostic implication of +1q has not been evaluated in the setting of standard triplet regimens. We retrospectively analyzed 201 consecutive patients with newly diagno...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Timothy M., Barwick, Benjamin G., Joseph, Nisha, Heffner, Leonard T., Hofmeister, Craig C., Bernal, Leon, Dhodapkar, Madhav V., Gupta, Vikas A., Jaye, David L., Wu, Jiayi, Goyal, Subir, Chen, Zhengjia, Boise, Lawrence H., Lonial, Sagar, Nooka, Ajay K., Kaufman, Jonathan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877577/
https://www.ncbi.nlm.nih.gov/pubmed/31767829
http://dx.doi.org/10.1038/s41408-019-0254-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877577/
https://www.ncbi.nlm.nih.gov/pubmed/31767829
http://dx.doi.org/10.1038/s41408-019-0254-0

Ejemplares similares